A recent interview I did with Investor’s Business Daily covered many hot drug-pricing topics. The launch of Sovaldi, angry reactions from PBM Express scripts and concerned physicians and patients have provoked a lot of dialogue globally on drug pricing and affordability.
This is all happening at a time when cost concerns for oncology and other specialty drugs are already in the spotlight. As one of the consequences, it has triggered medical associations such as the American Society of Clinical Oncology (ASCO) to introduce “financial toxicity” as one of the considerations in clinical guideline development.
In the interview, I tried to explain the relative complex issues and gave perspective on how this is impacting the pharmaceutical industry.
As always, I appreciate your reactions.